UK patent practice on human embryos post-WARF

The Intellectual Property Office in the UK issued a notice earlier this month on inventions involving human embryonic stem cells. The text runs as follows:
"Advances in stem cell technology raise questions about the patentability of:

* stem cells which have been isolated from human embryos, and
* processes involving these cells.
Uncertainty about what can be patented in this field may arise because the Patents Act 1977, as amended to implement Directive 98/44/EC on the legal protection of biotechnological inventions, does not directly address the patentability of human embryonic stem cells.

This Notice sets out the Intellectual Property Office’s general practice on the patentability of inventions involving such stem cells, although each case will be treated on its own merits in the light of all the relevant circumstances. Moreover, the Office's practice is subject to any future guidance from the UK courts.

This Notice supersedes a previous Notice of the same title issued in April 2003. It reflects an update in the Office's practice to take account of the recent WARF decision [briefly noted by the IPKat here] from the European Patent Office Enlarged Board of Appeal (EBoA), which has addressed the patentabilty of human embryonic stem cell cultures. The EBoA held as unpatentable those products (namely, human embryonic stem cell cultures) which at the filing date of the patent application in question could only be obtained from a method which involved the destruction of human embryos. However, the EBoA concluded that the decision “is not concerned with the patentability in general of inventions relating to human stem cells or human stem cell cultures.”

The Office has reconsidered its practice in this area in light of this decision.

(i) Processes for obtaining stem cells from human embryos

According to Paragraph 3(d) of Schedule A2 to the Patents Act 1977 uses of human embryos for industrial or commercial purposes are not patentable inventions. On this basis, the Office will not grant patents for processes of obtaining stem cells from human embryos.

(ii) Human totipotent cells

Human totipotent cells have the potential to develop into an entire human body. In view of this potential, such cells are not patentable because the human body at the various stages of its formation and development is excluded from patentability by Paragraph 3(a) of Schedule A2 to the Patents Act 1977. The Office will therefore not grant patents for human totipotent cells.

(iii) Human embryonic pluripotent stem cells

Human embryonic pluripotent stem cells, which arise from further division of totipotent cells, do not have the potential to develop into an entire human body, and can be grown in culture and the cell lines stored in cell banks. Although there is some opposition in the United Kingdom to research involving embryonic stem cells, a number of reports from influential UK political, medical and scientific bodies [1] in recent years have emphasised the enormous potential of stem cell research, including embryonic stem cell research, to deliver new treatments for a wide range of serious diseases. This indicates that on balance the commercial exploitation of inventions concerning human embryonic pluripotent stem cells would not be contrary to public policy or morality in the United Kingdom. Thus, the Office will continue to grant patents for inventions involving such cells provided they satisfy the normal requirements for patentability and provided that, at the filing or priority date, the invention could be obtained by means other than the destruction of human embryos".
The IPKat, who thanks his friend Sophie Maughan for spotting this, notes that nothing in the foregoing text affects the patentability of embryonic stem cells belonging to fictional cats.

More on human embryonic stem cells here
How to make good porridge here
UK patent practice on human embryos post-WARF UK patent practice on human embryos post-WARF Reviewed by Jeremy on Friday, February 20, 2009 Rating: 5

No comments:

All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here:

Powered by Blogger.